Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Biochemical response rate (Phase II)

  Measured over: from date of randomization up to approximately 24 months

• Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II

  Measured over: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later

• Tolerability of the proposed dose of AAA817- Phase II

  Measured over: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817

• Radiographic progression-free survival (rPFS)- Phase III

  Measured over: from date of randomization up to approximately 24 months

• Overall survival (OS)- Phase III

  Measured over: from date of randomization up to approximately 24 months

Changes Tremor has spotted